HIV-Associated Comorbidities, Coinfections and Complications

A complex array of coinfections and comorbid conditions, including end-organ  dysfunction, adversely affect the clinical course of HIV.  ART significantly improves but does not eliminate the development of HIV-associated comorbidities, coinfections, and complications (CCCs) which entails clinical management of concurrent HIV-associated CCCs across the lifespan. Several ERC-CFAR investigators are focused on determining the mechanistic basis and ameliorating the impact of infections such as tuberculosis (TB), hepatitis B and C, human  papillomavirus (HPV), and sexually transmitted infections  (STIs) on HIV disease course. Increasing our understanding of the underlying mechanisms responsible for how coinfections  and comorbid conditions impact on clinical course should lead to improved treatment and prevention of HIV infection and these related  disorders.  In addition, ERC-CFAR Investigators are engaged in research relevant to other coinfections and  opportunistic infections and HIV-related cancers, neurologic and  cognitive disorders, cardiovascular disease, mental illness and  substance use, metabolic and bone abnormalities, and liver  and renal dysfunction. Listed below are NIH-funded studies by our ERC-CFAR Investigators researching strategies to address HIV-associated Comorbidities, Coinfections, and Complications.